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Objectives: To describe the effectiveness of suppressiv  antibiotic treatment (SAT) in routine 2 
clinical practice when used in situations in which removal of a prosthetic implant is considered 3 
essential for the eradication of an infection, and it cannot be performed. Materials/methods: This 4 
was a descriptive retrospective and multicentre cohort study of prosthetic joint infection (PJI) 5 
cases managed with SAT. SAT was considered to have failed if a fistula appeared or persisted, 6 
if debridement was necessary, if the prosthesis was removed due to persistence of the infection, 7 
or if uncontrolled symptoms were present. Results: In total, 302 patients were analysed. Two 8 
hundred and three of these patients (67.2%) received monotherapy. The most commonly used 9 
drugs were tetracyclines (39.7% of patients) (120/302) and cotrimoxazole (35.4% of patients) 10 
(107/302). SAT was considered successful in 58.6% (177/302) of the patients (median time 11 
administered, 36.5 months; IQR [20.75-59.25]). Infection was controlled in 50% of patients at 12 
five years according to Kaplan-Meier analysis. Resistance development was documented in 15 13 
of 65 (23.1%) of the microbiologically documented cases. SAT failure was associated with age 14 
<70 years (sub-hazard ratio (SHR) 1.61, 95% CI [1.1-2.33]), aetiology other than gram-positive 15 
cocci (SHR 1.56, 95% CI [1.09-2.27]), and location of the prosthesis in the upper limb (SHR 16 
2.4, 95% CI [1.5-3.84]). SAT suspension was necessary due to adverse effects in 17 of 302 17 
patients (5.6%). Conclusions: SAT offers acceptable results for patients with PJI when surgical 18 
treatment is not performed or when it fails to eradic te the infection. 19 
 20 
INTRODUCTION 21 
Treatment of prosthetic joint infections (PJIs) aims to improve or preserve the function of the 22 
implant, prevent pain and eradicate the infection. Combined medical and surgical therapy is 23 
always necessary to eradicate infection(1). Removal f the implant is mandatory in chronic 24 
PJI(2) but acute PJIs can be managed by debridement, antibiotics and implant retention 25 
(DAIR)(3,4). Clinicians can, however, face situations in which surgical management, for 26 
4 
 
various reasons, is not optimal or does not occur, and therefore, the goal of eradicating the 1 
infection is abandoned. Thus, the option of using suppressive antibiotic therapy (SAT) without 2 
removing the prosthesis emerges. SAT can be defined as the indefinite administration of 3 
antibiotics with the objective of reducing the patien ’s symptoms and/or preventing progression 4 
of the infection. There was heterogeneity in previous studies about SAT, not only in the 5 
selection of patients but also in the criteria used to evaluate SAT success or failure. The reported 6 
success rates varied from 23.1% to 86.2%(5–8). In addition, the number of patients included 7 
was small, and information on the adverse effects of prolonged administration of antibiotics was 8 
not usually recorded. Overall, the efficacy of SAT and the factors that determine this efficacy, 9 
such as considerations related to the choice, dosage, and safety of the antibiotics used, are 10 
currently unknown.  11 
The aim of our study was to describe the effectiveness of SAT in routine clinical practice when 12 
used in patients with chronic PJIs in whom the implant is not removed or in patients with acute 13 
PJIs after failure of the DAIR strategy; both are situations in which removal of the implant is 14 
considered essential for eradication of the infection. The secondary objectives of the study were 15 
to analyse the factors associated with failure of SAT and to evaluate its safety. 16 
 17 
MATERIALS AND METHODS 18 
This was a retrospective, multicentre, cohort study of patients with PJI who were managed with 19 
SAT. The study was conducted in 29 hospitals within e collaboration of the European Study 20 
Group of Implant-Associated Infection (ESGIAI) and the Grupo de Estudio de Infección 21 
Osteoarticular (GEIO). In every participating centre, the clinician expert in bone and joint 22 
infections was instructed to include all consecutive PJI cases managed by SAT that met the 23 
inclusion criteria. The observation period was from October 2003 to September 2016. 24 
Patients were considered to have a PJI if at least one of the following conditions occurred: 1) a 25 
fistula communicating with the prosthesis; 2) local inf ammatory signs together with elevated 26 
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C-reactive protein (CRP), radiological signs of infection and positive cultures; 3) synovial fluid 1 
count >4,300/mm3 with >80% neutrophils (hip) or >1,100/mm3 with >64% neutrophils (knee) in 2 
chronic infections(9,10); 4) the same microorganism was isolated from at least two samples of 3 
intraoperative cultures. 4 
The PJIs were classified according to modified Tsukayama criteria(11). Briefly, the PJIs were 5 
classified as early postoperative (first three months after surgery), late chronic (symptoms not 6 
acute after three months), haematogenous (acute symptoms in a previously asymptomatic joint) 7 
and positive intraoperative culture (unsuspected septic loosening diagnosed during surgery) 8 
(Table S1, supplemental material). The inclusion criteria were as follows: 1) age over 18 years; 9 
2) received SAT for a PJI in which a potentially curative surgical treatment had not been 10 
performed; and 3) follow-up of at least 6 months.  11 
We defined SAT as the indefinite administration of antibiotics with a non-curative intention, in 12 
the context of either a PJI for which cure would require complete removal of the implant (as 13 
occurs for late chronic infections or an acute infection for which conservative treatment such as 14 
DAIR has failed).  15 
SAT failure was indicated by the appearance or persist nce of a fistula, the need for 16 
debridement or replacement of the prosthesis due to p rsistence of the infection, or the presence 17 
of uncontrolled symptoms. In cases in which none of these events occurred, the SAT was 18 
considered successful. Death was considered a SAT failure only if, in the opinion of the 19 
researcher, it was related to the PJI.  20 
Epidemiological variables, the aetiology of the infections, the reason SAT was chosen, the type 21 
of surgery, the antibiotics used, the adverse effects and the clinical evolution until the last visit 22 
were collected. The information was recorded in a centralized electronic database. Qualitative 23 
variables were described as absolute and relative frequencies, while quantitative variables were 24 
described as the mean and standard deviation if thedistribution was normal and as the median 25 
and interquartile range (IQR) if it was not. Quantitative variables were statistically analysed 26 
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using the Chi-squared test. To compare qualitative variables with quantitative variables, 1 
Student’s t-test or ANOVA was performed according to the number of categories. 2 
To evaluate the effect of SAT during and in the presence of competing events, the Fine-Gray 3 
competing risk regression model (1999) was used to estimate the sub-hazard ratio 4 
(SHR)(12,13). The variables that were clinically relevant and statistically significant in the 5 
univariate model were included in the multivariate model. Statistical significance was defined as 6 
p<0.05. Death was considered a competing event. To quantify the variability between hospitals, 7 
the median odds ratio (MOR) was calculated. This value indicates the median of the OR of SAT 8 
failure between two hospitals(14). The study was approved by the Ethics and Clinical Research 9 
Committee of the hospital with which the study coordinating team is associated.  10 
 11 
RESULTS 12 
A total of 340 patients with PJI participated in the study. Twenty-one cases were excluded due 13 
to insufficient or confounding data, and 17 cases wre excluded because they did not meet the 14 
inclusion criteria. Therefore, 302 cases were finally nalysed. 15 
Table 1 presents a description of the patients, and Table 2 lists the microorganisms that were 16 
isolated. Most of the cultures were monomicrobial, although 41/302 patients (13.6%) had two or 17 
more microorganisms. The main reasons that non-curative surgical management was not 18 
performed were the decision of the surgeon in 82/302 cases (27.2%), high surgical risk in 19 
80/302 cases (26.5%), advanced age in 71/302 cases (23.5%), the patient's decision in 70/302 20 
cases (23.2%), the anticipation of poor functional results in 69/302 cases (22.8%), and the 21 
presence of minor symptoms in 35/302 cases (11.6%). In 157/302 patients (52.0%), several of 22 
these reasons occurred simultaneously.  23 
SAT was administered for a median of 36.5 months (IQR [20.75-59.25]). For 17/302 patients 24 
(5.6%), the clinicians chose intermittent antibiotic administration with fixed antibiotic-free 25 
periods. Only 103/302 patients (34.1%) started SAT intravenously, and this practice was 26 
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performed regardless of age. Most patients (203/302 patients, 67.2%) underwent SAT regimens 1 
that used a single antibiotic, and 54/302 patients (17.9%) started with a combination regimen 2 
that was subsequently simplified to monotherapy. Thirty patients (9.9%) received a combination 3 
of antibiotics throughout SAT, and 15/302 patients (5.0%) started with a single antibiotic but 4 
later had a second drug added to their regimen due to lack of response. 5 
The most commonly used oral antibiotics were tetracyclines, followed by cotrimoxazole. Figure 6 
1 shows the mean and cumulative months of treatment per patient for each group of antibiotics. 7 
Seventy patients (23.2%) received rifampicin in combination with another antibiotic for a 8 
median of 3.8 months (IQR [1.9-12.0]).  9 
SAT was considered successful in 177 patients (58.6%) and failed in 125 of 302 patients 10 
(41.4%). The most frequent reason for failure was a need to remove the prosthesis, which 11 
occurred 61 of 125 times (48.8%), followed by presence of a fistula in 31 patients (24.8%), need 12 
for debridement in 19 patients (15.2%), and poor symptom control in 14 patients (11.2%). 13 
Figure S1 (supplementary material) shows the patients’ symptoms and CRP levels at the 14 
beginning of SAT and at the last follow-up for patients with successful SAT and for patients in 15 
whom SAT failed.  16 
Ninety-two patients (30.5%) required hospitalization after initiating SAT for a cause related to 17 
the PJI. The median follow-up to a failure event or death was 25 months (IQR [12-40]). In total, 18 
46/302 patients (15.2%) died during the follow-up period, none for a reason directly related to 19 
the PJI. Success rates of approximately 75% and 50% were observed at two years and five 20 
years, respectively (Figure 2). Thirty-four percent of the patients who experienced success 21 
received SAT for at least 4 years (Figure S2). 22 
There was microbiological documentation of failure in 65 patients of 125 (52%). Among the 23 
possible causes for the failure of SAT, the reported causes were the suspension of SAT in 24 
21/125 cases (16.8%), the development of resistance i  15 cases (of 65, 23.1% of 25 
microbiologically documented cases), the appearance of an unsuspected microorganism in 14 26 
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cases (of 65, 21.5% of microbiologically documented cases), and poor adherence to treatment in 1 
nine cases of 125 (7.2%). However, in 67/125 cases (53.6%), the cause of the SAT failure was 2 
unknown. 3 
The univariate and multivariate risk factors for failure are shown in Table 3. Competing risk 4 
analysis showed that the following independent variables were associated with SAT failure: age 5 
younger than 70 years, aetiology other than gram-positive cocci, and location of the prosthesis 6 
in the upper limb. In the multilevel model, the MOR adjusted for the number of hospital beds 7 
was 1.5 (IOR (interval odds ratio)[1.2-2.8]). This variability did not change if the variable is 8 
included in the multivariate model (MOR 1.54). We found no relationship between the use of 9 
quinolones and success or failure in patients whose infections were due to GNB (SHR 0.77, 10 
95% CI [0.33-1.80], p 0.55). Rifampicin use was notassociated with success or failure of SAT 11 
in PJI due to GPC (SHR 1.13, 95% CI [0.25-5.16], p 0.88). 12 
During the follow-up period, 104 adverse effects were recorded in 81/302 patients (26.8%); the 13 
majority of these were gastrointestinal (16.9%) and cutaneous (5.3%). Overall, 23 patients 14 
presented more than one adverse effect. However, SAT was suspended in only 17/302 patients 15 
(5.6%), while 46/302 (15.2%) changed antibiotics to avoid the adverse effect. Only three 16 
patients (1%) developed Clostridium difficile infection (Table S2, supplementary material). 17 
 18 
DISCUSSION 19 
In our study, the included patients suffered from a previously failed DAIR or an established 20 
chronic infection and lacked potentially curative surgical management. In this context, the 21 
probabilities of remaining infection-free at two years and five years are approximately 75% and 22 
50%, respectively.  23 
The efficacy of SAT was indirectly demonstrated by B ren et al. In their cohort study of 24 
patients with PJIs who were  managed using DAIR and prolonged antibiotic therapy, the rate of 25 
failure was four times higher in patients who discontinued their antibiotic treatment than in the 26 
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remaining patients, regardless of whether the infection was acute or chronic(7). The success 1 
rates reported in various studies range from 23% to 86%. The studies reporting the highest 2 
success rates included patients with early postoperativ  infections(6,8,15–17). In addition, the 3 
criteria used to define SAT success or failure also vary across studies. In the only controlled 4 
study published to date(18), Siqueira et al found a SAT efficacy of 68.5% at five years versus 5 
an efficacy of 41.1% in a control group of patients who did not receive SAT selected by a 6 
propensity score. The study included patients in whom a potentially curative surgery had been 7 
performed, and it considered death as a failure.  8 
The efficacy shown in our study appears acceptable in the context of the population managed by 9 
SAT, and this information is useful in decision-making in daily clinical practice. Moreover, our 10 
data show (Figure S1) that patients for whom SAT is successful exhibit better symptomatic and 11 
functional control than those who experience SAT failure. However, taking into account the 12 
implications of maintaining long-term antibiotic treatment, the indication for SAT must be 13 
weighed carefully, and the temptation to use this strategy to circumvent the challenge of 14 
complex surgeries that can be curative should be avoided(19). 15 
In our study, aetiologies other than gram-positive cocci or localization of the implant in an 16 
upper limb were independently associated with SAT failure. The finding that age younger than 17 
70 years is a factor associated with failure is not easily explained, but it may be associated with 18 
confounding variables that are related to the frequency of more complex cases in young patients 19 
and/or to, the presence of bone tumours, which in a previous study was associated with worse 20 
results (20). Therefore, it is likely that anatomical, biological, or microbiological factors that 21 
cannot be captured by reviewing the clinical data underlie many SAT failures. Interestingly, few 22 
failures were due to the development of antibiotic resistance. It is also relevant that in some 23 
cases, failure could be due to the existence of unsuspected microorganisms that were not 24 
detected in cultures prior to the initiation of SAT.  25 
Tetracyclines and cotrimoxazole were the most commonly used antibiotics, and their 26 
association with adverse effects was low. Few patients had to suspend treatment due to adverse 27 
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effects, and in cases in which it was suspended, an alternative regimen could nearly always be 1 
offered. The lack of association of success with the class of antibiotic used suggests that priority 2 
should be given to safety and tolerability when choosing an antibiotic from those that show 3 
microbiological activity against the causative organism. 4 
Our study has obvious limitations. The retrospectiv nature of the study makes it difficult to 5 
obtain detailed information on adverse effects or adherence. In addition, patients with very early 6 
failure of SAT were not included, resulting in overestimation of the success rate. The 7 
multicentre nature of the study also makes it likely that there was heterogeneity in the choice of 8 
antibiotic treatment and surgical management. The failure rate among the centres, as measured 9 
by the MOR, was 1.5; this indicates that the risk of SAT failure increases, on average, by 50% 10 
according to the centre in which it is performed and suggest that there are differences in the 11 
selection or management of patients in different cetres (21,22). Despite the fact that a large 12 
recruitment period was selected, the mean follow-up time was lower than expected. Only 43 of 13 
the successful patients (approximately one quarter of them) were followed for more than 5 years 14 
(Figure S2). Finally, the absence of a control group makes it impossible to accurately quantify 15 
the benefit of SAT. 16 
However, some of the characteristics of our study demonstrate its value compared to previously 17 
published investigations. Our study is the largest published study to date to address the use of 18 
SAT for PJIs. Only patients with active infections and whose cure probability was null or 19 
extraordinarily low were included. We chose pragmatic criteria to define SAT failure. 20 
Nevertheless, the success of SAT may be underestimated because we cannot rule out the 21 
possibility that some patients with intermittent fistula benefitted from SAT. Finally, the 22 
competing event analysis allowed us to analyse the failure of the patients who were alive at each 23 
point examined.  24 
In conclusion, when prescribed by experts who can anticipate the toxicities and interactions that 25 
may occur during antibiotic treatment, SAT offers acceptable results in terms of its efficacy and 26 
safety for patients for whom surgical treatment is in ufficient or is contraindicated due to 27 
11 
 
disproportionate risks involving the patient's symptoms or his or her life expectancy. 1 
Considering the practical (and ethical) difficulties associated with conducting a clinical trial, 2 
well-followed prospective cohort studies may continue to advance our knowledge of the 3 
complex issue of the use of SAT in PJI. 4 
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Table 1: Characteristics of the patients 1 
 n (302) % 
Sex    Male 





Age       >70 years 












































Inflammatory and radiological signs, with 
elevated CRP and positive culture 
























Charlson index (median, IQR) 
Diabetes 
Solid neoplasm  

















Initial clinical symptoms 
Asymptomatic 
Pain 
Impaired walking  
Fistula 
Local inflammation 
             Joint effusion 


















Debridement with partial removal 










Reason for non-curative surgical management 
Decision of the surgeon 
High surgical risk 
Advanced age 
Patient´s decision 
Anticipation of poor functional results 















Percentages were calculated relative to the total number of patients. The mean and standard 2 
deviation were calculated for normally distributed variables, and the median and interquartile 3 
range were calculated for variables with an abnormal distribution. n: number of patients; IQR: 4 
interquartile range; SD: standard deviation.   5 
1after failure of DAIR.  6 
2Only one patient had a synovial count of leukocytes as a unique criterion of PJI. 7 
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Anticipation of poor functional results 









Percentages were calculated relative to the total number of patients. The mean and standard 31 
deviation were calculated for normally distributed variables, and the median and interquartile 32 
range were calculated for variables with an abnormal distribution. n: number of patients; IQR: 33 
interquartile range; SD: standard deviation.   34 
1after failure of DAIR.  35 
2Only one patient had a synovial count of leukocytes as a unique criterion of PJI. 36 
3Patients for whom this variable was reported. 37 
Table 2. Aetiology of prosthetic joint infections 1 
Microorganism n (%) 
CoNS 98 (32.5) 
S. aureus 
   MSSA 




Streptococcus sp. 28 (9.3) 



























Fungi 6 (2.0) 
Negative culture 22 (7.3) 
Polymicrobial 41 (13.6) 
High virulence 144 (47.7) 
CoNS: Coagulase-negative staphylococci; MSSA: methicillin-sensitive Staphylococcus aureus; 2 
MRSA: methicillin-resistant S. aureus; sp.: species; GNB: gram-negative bacilli; GPB: gram-3 
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Fungi 6 (2.0) 
Negative culture 22 (7.3) 
Polymicrobial 41 (13.6) 
High virulence 144 (47.7) 
CoNS: Coagulase-negative staphylococci; MSSA: methicillin-sensitive Staphylococcus aureus; 17 
MRSA: methicillin-resistant S. aureus; sp.: species; GNB: gram-negative bacilli; GPB: gram-18 
positive bacilli. “High virulence” is defined as infections caused by S. aureus, GNB, and yeast. 19 
 20 
Table 3: Analysis of the variables associated with SAT failure 
 Success Failure Univariate analysis1 Multivariate analysis2 
 n %  n % SHR 95% CI p SHR 95% CI p 
Sex    Male 
          Female 
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1Univariate analysis of the analysed variables and their association with failure of the SAT.  
2Multivariable model of the variables associated with failure of the SAT.  
3The analysis included all the GPC (Streptococci, Staphylococci and Enterococci).  
n: number of patients; SD: standard deviation, IQR: interquartile range; SHR: sub-hazard ratio; 
CI: confidence interval; GPC: gram-positive cocci; CoNS: coagulase-negative staphylococci; 
MRSA: methicillin-resistant S. aureus. 
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3The analysis included all the GPC (Streptococci, Staphylococci and Enterococci).  
n: number of patients; SD: standard deviation, IQR: interquartile range; SHR: sub-hazard ratio; 
CI: confidence interval; GPC: gram-positive cocci; CoNS: coagulase-negative staphylococci; 
MRSA: methicillin-resistant S. aureus. 











The columns of the graph represent the total number of months of treatment per patient for each 
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302 246 171 108 74 51 31 17 8 5 1 0 0 
Number at risk
0 12 24 36 48 60 72 84 96 108 120 132 144
Months
1  
